Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Artiva reported a Q2 net loss of $25.0 million, or $(0.63) per share, while ending the quarter with a strong cash position of $349.4 million following a recent $300 million public offering. The company achieved a key regulatory milestone with the FDA granting RMAT designation to AlloNK plus rituximab for refractory rheumatoid arthritis, facilitating a Phase 3 registrational trial slated to begin in the second half of 2026.
Key figures
- Net Loss
- 25000000
- Drug Name
- AlloNK (AB-101)
- Ga Expenses
- 5000000
- Rd Expenses
- 21900000
- Cash Position
- 349400000
- Deal Value Usd
- 300000000
- Phase Of Trial
- Phase 3
- Runway
- into 2029
- Acr50 response rate
- 71%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.